Small molecule inhibitors targeting the EGFR/Eps8 complex in NSCLC and breast cancer models have shown promising results, supporting Eps8 as a potential therapeutic target in cancer (Li et al, 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.